Compare Stocks

→ A new way to collect income from stocks (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

No chart data

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AST Asterias Biotherapeutics	$0.00	$0.00	$0.51 ▼ $2.05	$111K	N/A	136,653 shs	1,000 shs

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Did You Get Your Free Bitcoin Yet? (Ad)

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AST Asterias Biotherapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AST Asterias Biotherapeutics	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AST Asterias Biotherapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AST Asterias Biotherapeutics	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AST Asterias Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
AST Asterias Biotherapeutics	N/A

Insider Ownership

Company	Insider Ownership
AST Asterias Biotherapeutics	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AST Asterias Biotherapeutics	N/A	55.66 million	N/A	Not Optionable

ZLD, TILS, RAC, and AST Headlines

Source	Headline
	CLDI Calidi Biotherapeutics, Inc. seekingalpha.com - March 27 at 8:25 AM
	Protalix BioTherapeutics Inc PLX morningstar.com - February 17 at 11:04 PM
	Calidi Biotherapeutics Stock (AMEX:CLDI) Dividends: History, Yield and Dates benzinga.com - November 27 at 9:49 AM
	Barinthus Biotherapeutics PLC ADR morningstar.com - November 22 at 6:14 PM
	Calidi Biotherapeutics Inc Ordinary Shares - Class A morningstar.com - November 2 at 12:42 AM
	Arcutis Biotherapeutics Stock (NASDAQ:ARQT), Analyst Ratings, Price Targets, Predictions benzinga.com - July 18 at 5:56 PM
	Iovance Biotherapeutics (NASDAQ: IOVA) fool.com - May 21 at 8:16 AM
	Human Embryonic Stem Cells (HESC) Market Future Investments and Forecast Till 2030 marketwatch.com - May 11 at 9:05 PM
	BrightPath Biotherapeutics Co Ltd (4594) investing.com - May 8 at 3:29 PM
	BrightPath Biotherapeutics Co., Ltd. asia.nikkei.com - April 27 at 7:52 PM
	Human Embryonic Stem Cells (HESC) Market: Analyzing Growth Opportunities and Industry Trends for 2023-2028 marketwatch.com - March 14 at 6:50 PM
	2023-2029 Human Embryonic Stem Cells (HESC) Market Size and Regional Analysis \| Research Report by Absolute Reports marketwatch.com - March 9 at 8:02 AM
	Stem Cell Therapy for Osteoarthritis Market Expert Industrial Investigation Report 2023-2028 marketwatch.com - March 7 at 3:39 AM
	Therapeutic Cancer Vaccines Market 2023 \| Global Industry Report Forecast 2029 marketwatch.com - March 6 at 10:38 PM
	Emerging Opportunities in Therapeutic Cancer Vaccines Market from 2023 to 2027 marketwatch.com - February 27 at 7:52 AM
	Atara Biotherapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation seekingalpha.com - February 20 at 12:18 AM
	Therapeutic Cancer Vaccines Market Outlook 2023 and Forecast to 2028 with Top Countries Data marketwatch.com - February 14 at 10:23 AM
	Bridge Biotherapeutics to Present at BIOTECH SHOWCASE™ 2023 finance.yahoo.com - January 30 at 3:03 PM
	SONN Sonnet BioTherapeutics Holdings, Inc. seekingalpha.com - January 20 at 6:58 PM
	Human Embryonic Stem Cells (HESC) Market By Industry Research, Supply, Size, Share and Prospects 2023-2028 marketwatch.com - January 19 at 9:05 AM
	Sonnet BioTherapeutics Shares Up 8% on Roche Collaboration marketwatch.com - January 11 at 8:03 PM
	Kling Biotherapeutics Appoints Michael Koslowski, M.D. As Chief Executive Officer finance.yahoo.com - January 5 at 7:35 AM
	Sensei Biotherapeutics Slashes Workforce, Closes R&D Site finance.yahoo.com - December 20 at 6:29 PM
	Human Embryonic Stem Cells (HESC) Market 2022 Statistics, Industry Share, Latest Trends, Growth Drivers, Size Estimate and Forecast till 2028 marketwatch.com - November 27 at 8:55 AM

Top Headlines

3 High Dividend Stocks to Replace Lower Savings Yields Ahead
April 9, 2024 9:15 AM
View 3 High Dividend Stocks to Replace Lower Savings Yields Ahead
Analysts are Bullish on These 4 Oversold Large Cap Stocks
April 1, 2024 11:37 AM
View Analysts are Bullish on These 4 Oversold Large Cap Stocks
3 Key Stocks Helping to Drive the EV Race
April 12, 2024 9:25 AM
View 3 Key Stocks Helping to Drive the EV Race
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
April 12, 2024 7:32 AM
View 2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Low VIX? 3 High Beta Stocks To Boost Your Returns
March 27, 2024 9:01 AM
View Low VIX? 3 High Beta Stocks To Boost Your Returns

All Headlines

Company Descriptions

Asterias Biotherapeutics

NYSEAMERICAN:AST

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial